Skip to main content

Investment Criteria

Investment Criteria

TVI seeks to partner with entrepreneurial companies and individuals offering superior emerging product or technology opportunities, hallmarked by a clear strategic plan and a management team with the capabilities to ensure effective execution. These opportunities should signal the potential for significant value creation through, for example, improved efficiencies in drug discovery and development, identification of new therapeutic targets or the introduction of innovative, new drug candidates.

Sector Focus: Therapeutics

TVI intends to maintain a diverse investment portfolio, but is presently concentrating on drugs and biotherapeutics to treat cancer, metabolic disorders (obesity, diabetes, and dyslipidemias), cardiovascular disorders (heart failure, peripheral artery disease, etc.), chronic inflammatory and immune disorders (rheumatoid arthritis, systemic lupus erythematosus, psoriasis, COPD and asthma) and diseases of the central nervous system (specifically Alzheimer's disease and schizophrenia). Additional areas of strategic importance include gastroenterology (inflammatory bowel disease, irritable bowel syndrome and fibrosis/cirrhosis) and renal/urological disease (chronic kidney disease, acute kidney injury, etc.), TVI's focus also includes regenerative medicines, novel vaccines technologies and innovative protein and peptide biotherapeutics. Currently, TVI does not invest in anti-infective diseases, medical devices, or diagnostics platforms.

Sector Focus: Targets and Technologies

TVI is interested in enabling technologies that enhance drug target discovery and lead identification, increase the efficiency of lead optimization and eliminate redundancies in existing discovery operations. In general, these technologies will be a significant advance over existing systems and processes, and have the potential to provide competitive advantage.

Investor Stake

TVI maintains a flexible approach to all investment opportunities. However, our preference is to hold <15% equity interest as co-investors, where the lead investors would include venture capital firms, private equity funds, angels, or institutional investors.